Clinical Trials
95 trialsDonor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
UPCC 25406
Abramson Cancer Center at Penn Medicine
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Fred Hutchinson Cancer Center
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
City of Hope Medical Center
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
University of Nebraska
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
University of Nebraska
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
OHSU Knight Cancer Institute
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Dana-Farber Cancer Institute
BMT CTN 0202
Medical College of Wisconsin
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Case Comprehensive Cancer Center
UF-AML-CE-101
University of Florida
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
Medstar Health Research Institute
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
RTOG Foundation, Inc.
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
University College, London
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Fred Hutchinson Cancer Center
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
University of California, San Francisco
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
Medical College of Wisconsin
Treatment of Tumors of the Choroid Plexus Epithelium
M.D. Anderson Cancer Center
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Therapeutic Advances in Childhood Leukemia Consortium
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Tufts Medical Center
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
M.D. Anderson Cancer Center
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Milton S. Hershey Medical Center
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
University of Florida
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Dana-Farber Cancer Institute
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
Children's Hospital of Philadelphia
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Seattle Children's Hospital
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
BENEFIT
Centre Leon Berard
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Milton S. Hershey Medical Center
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
Georgetown University
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University